

10/200487

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV323525866US, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: January 20, 2006

Signature:

(Mary Jane DiPalma)

1420133 100 100 JAN 2006

Docket No.: ASZD-P01-135
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Edwards et al.

Application No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Filed: January 20, 2006

Art Unit: Not Yet Assigned

For: GENETIC MARKER FOR CORONARY
ARTERY DISEASE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided with the exception of reference CD.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,

10/963437

Application No.: Not Yet Assigned

Docket No.: ASZD-P01-135

2006

publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-135.

Dated: January 20, 2006

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735

FISH & NEAVE IP GROUP

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

1AP20 REC'D PENDING 20 JAN 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	January 20, 2006
				First Named Inventor	Mark Richard Edwards
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	ASZD-P01-135

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-03/093816		11-13-2003	Bayer AG		
	BB	WO-04/000993		12-31-2003	Jankowski Marek		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Breton et al., "Presence of functional oxytocin receptors in cultured human myoblasts," The Journal of Clinical Endocrinology and Metabolism 87(3):1415-1418 (2002)			
	CB	Gimpl et al., "The oxytocin receptor system: Structure, function, and regulation," Physiological Reviews 81(2):629-683 (2001)			
	CC	Gutkowska et al., "Oxytocin is a cardiovascular hormone," Brazilian Journal of Medical and Biological Research 33(6):625-633 (2000)			
	CD	International Search Report from PCT/GB04/003181 (12/8/04)			
	CE	Jankowski et al., "Oxytocin and its receptors and synthesized in the rat vasculature," Proceedings of the National Academy of Sciences of the USA 97(11):6207-6211 (2000)			
	CF	Knox et al., "Social isolation and cardiovascular disease: An atherosclerotic pathway," Psychoneuroendocrinology 23(8):877-890 (1998)			
	CG	Micheli et al., "Polymorphism and genetic mapping of the human oxytocin receptor gene on chromosome 3," American Journal of Medical Genetics 60(3):183-187 (1995)			
	CH	Olson et al., "Mapping a cardiomyopathy locus to chromosome 3p22-p25," Journal of Clinical Investigation 97(2):528-532 (1996)			
	CI	Ostrowski et al., "Estrogen increases renal oxytocin receptor gene expression," Endocrinology 136(4):1801-1804 (1995)			
	CJ	Paquin et al., "Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes," Proceedings of the National Academy of Sciences of USA 99(14):9550-9555 (2002)			
	CK	Paredes et al., "Chronic Microdialysis of CNS peptides as a function of social environment in the white rabbit," Society for Neuroscience Abstract Viewer and Itinerary planner Abstract No. 713.13 Vol. 2003 (2003)			
	CL	Rice et al., "Genomewide linkage scan of resting blood pressure: Heritage Family Study. Health, Risk Factors, Exercise Training, and Genetics," Hypertension 39(6):1037-1043 (2002)			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete, if Known	
				Application Number	Not Yet Assigned 65487
				Filing Date	January 20, 2006
				First Named Inventor	Mark Richard Edwards
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	ASZD-P01-135

	CM	Sotgia et al., "Localization of the human caveolin-3 gene to the D3S18/D3S4163/D3S4539 locus (3p25), in close proximity to the human oxytocin receptor gene - Identification of the caveolin-3 gene as a candidate for deletion in 3p-syndrome," Febs Letters 452(3):177-180 (1999)	
	CN	Strakova et al., "ERK2 mediates oxytocin-stimulated PGE2 synthesis," The American Journal of Physiology 274(4):E634-E641 (1998)	
	CO	Zingg et al., "The oxytocin receptor," Trends in Endocrinology and Metabolism 14(5):222-227 (2003)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--